Our results suggest that levels of circulating CD137+ T cells could serve as biomarkers for predicting the response of (R/M) HNSCC patients to pembrolizumab treatment, thus contributing to the success of anti-cancer treatment. The gene discussed is TNFRSF9; the disease is head and neck squamous cell carcinoma.